Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 13/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.62 |
| ▸ | HTR2A | P28223 | 4/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | USP25 | Q9UHP3 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6251152 | 0.90 | MCHR1 (0.68) | MCHR1CHRM1HTR2ACYP2D6KDM4E | |
| SCHEMBL6705913 | 0.87 | MCHR1 (0.62) | MCHR1CHRM1HTR2ACYP2D6KDM4E | |
| SCHEMBL23269704 | 0.81 | LSS (0.57) | KDM4E | |
| SCHEMBL28757059 | 0.80 | USP25 (0.47) | MCHR1CHRM1HTR2ACYP2D6HDAC1 | |
| SCHEMBL7703379 | 0.79 | HDAC6 (0.64) | MCHR1CHRM1HTR2ACYP2D6KDM4E | |
| SCHEMBL6704283 | 0.79 | MCHR1 (0.70) | MCHR1CHRM1HTR2ACYP2D6KDM4E | |
| SCHEMBL6705549 | 0.79 | MCHR1 (0.73) | MCHR1CHRM1HTR2ACYP2D6KDM4E | |
| SCHEMBL6250405 | 0.79 | MCHR1 (0.73) | MCHR1CHRM1HTR2ACYP2D6KDM4E | |
| SCHEMBL3870582 | 0.78 | MCHR1 (0.69) | MCHR1CHRM1HTR2ACYP2D6KDM4E | |
| SCHEMBL3875743 | 0.78 | MCHR1 (0.80) | MCHR1CHRM1HTR2ACYP2D6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | MCHR1 2/4885CHRM1 295/4885HTR2A 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.